OPKO Health, Inc.
$1.51B- Market cap
- $1.19B
- Debt
- +$687.93M
- Cash
- −$364.41M
Capital structure 63% equity / 37% debt · EV / Revenue 2.49x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: OPK stock price at premium vs DAN $1.59 current versus $0.36 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DAN's multiple
Implied fair value · at OPK's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OPK FY 2025 (ended Dec 31, 2025) · DAN FY 2025 (ended Dec 31, 2025).
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 63% equity / 37% debt · EV / Revenue 2.49x
Capital structure 51% equity / 49% debt · EV / Revenue 0.81x · EV / EBITDA 7.14x
DAN carries the larger enterprise value at $6.08B against $1.51B; DAN trades on the lower EV / Revenue multiple (0.81x vs 2.49x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OPKO Health, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Dana Incorporated · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.54x
3.79x
Net debt / EBITDA
Leverage against operating earnings
-3.03x
3.19x
Cash and equivalents
Liquid reserves on the balance sheet
$364.41M
$469.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMARIN CORP PLC\UK
OPK vs AMRN
Sarepta Therapeutics, Inc.
OPK vs SRPT
Amphastar Pharmaceuticals, Inc.
OPK vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
OPK vs SUPN
Harmony Biosciences Holdings, Inc.
OPK vs HRMY
LEAR CORP
OPK vs LEA
Adient plc
OPK vs ADNT
FOX FACTORY HOLDING CORP
OPK vs FOXF
AMERICAN AXLE & MANUFACTURING HOLDINGS INC
OPK vs AXL
$687.93M
$3.18B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.